Inrebic

• Inrebic (fedratinib) is a kinase inhibitor primarily targeting JAK2 and FLT3.
• It is approved for adults with intermediate-2 or high-risk myelofibrosis, including primary, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis.
• The drug works by inhibiting overactive enzymes that contribute to abnormal cell growth in myelofibrosis.
• Common side effects include gastrointestinal issues, anemia, and thrombocytopenia.
• Patients require regular monitoring for potential adverse reactions, including the risk of Wernicke’s encephalopathy.

What is Inrebic and How It Works

Inrebic is a prescription medication, generically known as fedratinib. It belongs to a class of drugs called kinase inhibitors, specifically targeting Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). It is approved for the treatment of specific types of myelofibrosis, a rare bone marrow disorder.

Inrebic works by inhibiting the activity of JAK2 and FLT3 kinases. In myelofibrosis, these kinases are often overactive, leading to abnormal cell growth and the development of disease symptoms. By blocking these enzymes, Inrebic helps to reduce the proliferation of abnormal blood cells, decrease spleen size, and alleviate disease-related symptoms such as fatigue, night sweats, and bone pain. This targeted action helps to restore more normal blood cell production in affected individuals.

What is Inrebic Used For and Important Drug Information

Inrebic is indicated for the treatment of adults with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. These conditions are types of chronic myeloproliferative neoplasms characterized by the abnormal production of blood cells in the bone marrow, leading to scarring (fibrosis) and impaired blood cell formation.

Inrebic drug information includes details on its administration, dosage, and potential interactions. It is typically taken orally once daily, with or without food. The dosage may be adjusted based on the patient’s response, tolerance, and kidney or liver function. It is crucial for patients to inform their healthcare provider about all other medications, supplements, and herbal products they are taking, as Inrebic can interact with various drugs, potentially altering its effectiveness or increasing the risk of side effects. For instance, strong CYP3A4 inhibitors can increase Inrebic exposure, while strong CYP3A4 inducers can decrease it.

Inrebic Side Effects and Safety Information

Like all medications, Inrebic side effects can occur, ranging from mild to severe. Common side effects often include gastrointestinal issues such as diarrhea, nausea, vomiting, and abdominal pain. Hematologic side effects like anemia and thrombocytopenia (low platelet count) are also frequently observed. Other potential side effects include fatigue, muscle spasms, and elevated liver enzymes. Patients should be aware of these potential reactions and discuss any concerns with their healthcare provider.

A serious but rare side effect associated with Inrebic is Wernicke’s encephalopathy, a neurological disorder caused by thiamine (vitamin B1) deficiency. Due to this risk, thiamine levels should be assessed before and during treatment, and supplementation may be recommended. Patients should be monitored for signs and symptoms of Wernicke’s encephalopathy, such as confusion, ataxia (impaired coordination), and ophthalmoplegia (paralysis or weakness of eye muscles). Regular monitoring of blood counts, liver function, and thiamine levels is essential throughout treatment to manage potential adverse reactions promptly. Patients should report any new or worsening symptoms to their healthcare provider immediately.

Common Inrebic side effects can include:

• Diarrhea
• Nausea and vomiting
• Anemia
• Thrombocytopenia (low platelet count)
• Fatigue
• Muscle spasms